RTI-177: Difference between revisions
CSV import |
CSV import |
||
| Line 19: | Line 19: | ||
[[Category:Phenyltropanes]] | [[Category:Phenyltropanes]] | ||
{{stub}} | {{stub}} | ||
== RTI-177 == | |||
<gallery> | |||
File:RTI-177 Structure.svg|RTI-177 Structure | |||
File:LMAgraph.GIF|LMA Graph | |||
File:RTI336.png|RTI336 | |||
File:HeteroCD.GIF|HeteroCD | |||
</gallery> | |||
Latest revision as of 01:37, 20 February 2025
RTI-177 is a psychoactive drug and research chemical that belongs to the phenyltropane group of substances. It is primarily used in scientific research and has not been approved for medical use. RTI-177 is known for its high affinity for the dopamine transporter (DAT), which it binds to more selectively than other similar compounds.
Etymology[edit]
The name "RTI-177" is an abbreviation of "Research Triangle Institute-177", with the number 177 being a sequential identifier in the series of compounds developed by the institute. The Research Triangle Institute (RTI) is a nonprofit organization based in the Research Triangle Park in North Carolina, USA, which conducts research in various fields including drug development.
Pharmacology[edit]
RTI-177 acts as a potent dopamine reuptake inhibitor, meaning it blocks the reabsorption of dopamine into the pre-synaptic neuron, leading to an increase in the extracellular concentration of dopamine. This results in increased neurotransmission and allows for prolonged effects of dopamine in the synaptic cleft, which can lead to various psychoactive effects.
Related Compounds[edit]
RTI-177 is part of a larger family of phenyltropane-based compounds developed by RTI. Other notable compounds in this family include RTI-31, RTI-32, RTI-51, RTI-55, RTI-112, RTI-113, RTI-121, RTI-126, RTI-150, RTI-171, RTI-229, RTI-336, and RTI-371.
